Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Haynes: B-Cell Lineage Envelope Design |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Screening |
| Species: | Non-Organism Study |
| Stage: | Assays Completed |
| Study Start Date: | 2014-05-27 |
| Study Made Public: | 2016-11-01 |
Title
Impact of IgG Subclass on Capacity to Mediate Neutralization of TH023.6
Description
CAVD 454 is an immunogenicity study to characterize the neutralization of monoclonal antibodies from RV144 human clinical trial vaccine recipients.
Sign in to see full information about this study and to download study data.
Products
ALVAC (vCP1521) AIDSVAX B/E Saline (non-specific) Placebo ALVAC Placebo AIDSVAX B/EIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.